Aurisco(SH:605116) Zheng Quan Zhi Xing·2025-08-29 16:18Core Viewpoint - Aorite Pharmaceutical Co., Ltd. reported a significant increase in revenue and profit for the first half of 2025, indicating strong operational performance and growth potential in the pharmaceutical industry [1]. Financial Performance - Total assets at the end of the reporting period reached approximately 3.90 billion RMB, a 0.65% increase from the previous year [1]. - Operating revenue for the period was approximately 822 million RMB, representing a 12.50% increase compared to the same period last year [1]. - Total profit amounted to approximately 268 million RMB, reflecting a 23.66% increase year-on-year [1]. - Net profit attributable to shareholders was approximately 235 million RMB, up 24.55% from the previous year [1]. - The net profit after deducting non-recurring gains and losses was approximately 226 million RMB, a 20.94% increase compared to the same period last year [1]. Shareholder Information - The top ten shareholders include Zhejiang Tongben Investment Co., Ltd. with a 37.81% stake and Chu Yizhou with a 27.65% stake [2][3]. - The total number of shareholders at the end of the reporting period was 11,771 [1].